Brief: Neurosense Therapeutics Expects To Report Results From Strategic Collaboration With Biogen Second Half Of January
09/01/2024 14:37
Jan 9 (Reuters) - Neurosense Therapeutics Ltd NRSN.O :
* NEUROSENSE RECAPS POSITIVE 2023 ACHIEVEMENTS INCLUDING
STATISTICALLY SIGNIFICANT SLOWING OF DISEASE PROGRESSION IN
PHASE 2B ALS TRIAL OF PRIMEC AND HIGHLIGHTS ANTICIPATED 2024
CATALYSTS
* NEUROSENSE THERAPEUTICS LTD - STATISTICALLY SIGNIFICANT
REDUCTION IN ALS DISEASE PROGRESSION IN PHASE 2B PARADIGM TRIAL
* NEUROSENSE THERAPEUTICS LTD - EXPECTS TO REPORT RESULTS
FROM
STRATEGIC COLLABORATION WITH BIOGEN IN SECOND HALF OF JANUARY
Source text for Eikon: ID:nPn3YMBPHa
Further company coverage: NRSN.O
((Reuters.Briefs@thomsonreuters.com;))